LifeVantage Q2 2026 Lifevantage Corp Earnings Call | AllMind AI Earnings | AllMind AI
Q2 2026 Lifevantage Corp Earnings Call
Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to today's conference call to discuss LifeVantage's second quarter of fiscal 2026 results. At this time, all participants are in a listen-only mode. Following the formal remarks, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up. Hosting today's conference call will be Reed Anderson with ICR. As a reminder, today's conference is being recorded. I would now like to turn the conference over to Mr. Anderson. Please go ahead, sir.
Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to today's conference call to discuss LifeVantage's second quarter of fiscal 2026 results. At this time, all participants are in a listen-only mode. Following the formal remarks, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up. Hosting today's conference call will be Reed Anderson with ICR. As a reminder, today's conference is being recorded. I would now like to turn the conference over to Mr. Anderson. Please go ahead, sir.
Speaker #1: Good day, gentlemen, and thank you for ladies and standing by. Welcome to today's conference call to discuss LifeVantage Corp second quarter of fiscal 2026 results.
Speaker #1: At this time , all participants are in a listen only mode . Following the formal remarks , we will conduct the question and answer session .
Speaker #1: Instructions will be provided at that time for you to queue up. Hosting today's conference call will be Reed Anderson with ICR. As a reminder, today's conference is being recorded.
Reed Anderson: Thank you. Good afternoon and welcome to LifeVantage Corporation's conference call to discuss results for the second quarter of fiscal 2026. On the call today from LifeVantage, with prepared remarks, are Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer. By now, everyone should have access to the earnings release, which went out this afternoon at approximately 4:05PM Eastern Time. If you have not received the release, it is available on the investor relations portion of LifeVantage's website at www.lifevantage.com. This call is being webcast, and a replay will be available on the company's website as well. Before we begin, I would like to remind everyone that our prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. These statements do not guarantee future performance, and therefore, undue reliance should not be placed upon them.
Reed Anderson: Thank you. Good afternoon and welcome to LifeVantage Corporation's conference call to discuss results for the second quarter of fiscal 2026. On the call today from LifeVantage, with prepared remarks, are Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer. By now, everyone should have access to the earnings release, which went out this afternoon at approximately 4:05PM Eastern Time. If you have not received the release, it is available on the investor relations portion of LifeVantage's website at www.lifevantage.com.
Speaker #1: I would now like to turn the call over to Mr. Anderson. Please go ahead, sir.
Speaker #2: Thank you. Good afternoon, and welcome to the LifeVantage Corp conference call to discuss results for the second quarter of fiscal 2026. On the call today from LifeVantage Corp with prepared remarks are Steve Fife, President and Chief Executive Officer.
Speaker #2: And Karl, our Chief Financial Officer. By now, everyone should have access to the release, which went out this afternoon at 4:05 p.m.
Speaker #2: approximately Eastern Time. If you have not received the release, it is available on the Investor Relations portion of the LifeVantage Corp website at LifeVantage Corp.
Reed Anderson: This call is being webcast, and a replay will be available on the company's website as well. Before we begin, I would like to remind everyone that our prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. These statements do not guarantee future performance, and therefore, undue reliance should not be placed upon them.
Speaker #2: This call is being webcast and a replay will be available on the company's website as well . Before we begin , I would remind like to everyone that our prepared remarks contain forward looking statements and management may additional make forward looking statements in response to your questions .
Reed Anderson: These statements are based on current expectations of the company's management and involve inherent risks and uncertainties, including those identified in the risk factors section of LifeVantage's most recently filed Forms 10-K and 10-Q. Please note that during today's call, we will discuss non-GAAP financial measures, including results on an adjusted basis. Management believes these financial measures can facilitate a more complete analysis and greater transparency into LifeVantage's ongoing results of operations, particularly when comparing underlying operating results from period to period. We've included reconciliation of these non-GAAP measures with today's release. This call also contains time-sensitive information that is accurate only as of the date of this live broadcast, 4 February 2026. LifeVantage assumes no obligation to update any forward-looking projection that may be made in today's release or call. Now, I will turn the call over to Steve Fife, the President and Chief Executive Officer of LifeVantage.
Reed Anderson: These statements are based on current expectations of the company's management and involve inherent risks and uncertainties, including those identified in the risk factors section of LifeVantage's most recently filed Forms 10-K and 10-Q. Please note that during today's call, we will discuss non-GAAP financial measures, including results on an adjusted basis. Management believes these financial measures can facilitate a more complete analysis and greater transparency into LifeVantage's ongoing results of operations, particularly when comparing underlying operating results from period to period.
Speaker #2: These statements do not guarantee future performance, and therefore undue reliance should not be placed upon them. These statements are based on current expectations of the company's management and involve inherent risks and uncertainties, including those identified in the Risk Factors section of LifeVantage Corp.
Speaker #2: Recently filed most forms and 10-Q. Please note that during today's call, we will discuss non-GAAP financial measures, including results on an adjusted basis.
Speaker #2: believes these Management financial measures can facilitate a more complete analysis and greater transparency into LifeVantage Corp results of operations , when particularly comparing ongoing underlying operating results from period .
Reed Anderson: We've included reconciliation of these non-GAAP measures with today's release. This call also contains time-sensitive information that is accurate only as of the date of this live broadcast, 4 February 2026. LifeVantage assumes no obligation to update any forward-looking projection that may be made in today's release or call. Now, I will turn the call over to Steve Fife, the President and Chief Executive Officer of LifeVantage.
Speaker #2: period to We've included a these non-GAAP reconciliation of measures with today's release . also Is call contains time sensitive information that is accurate only as of the date of this live broadcast .
Speaker #2: February 4th, 2026. LifeVantage Corp assumes no obligation to update any forward-looking statements or projections that may be made in today's release or call.
Steve Fife: Thanks, Reed, and good afternoon, everyone. Thank you for joining us today. The second quarter presented both challenges and opportunities as we navigated a rapidly evolving competitive landscape while executing on our strategic initiatives. While our Q2 revenue and earnings were down significantly from prior year levels, we were cycling the explosive launch of our MindBody GLP-1 System in October of last year. Despite this headwind, we made significant progress on several key fronts and remained well-positioned for long-term growth in the broader health and wellness ecosystem. As a management team, we acknowledge that our performance during the quarter did not meet your expectation or ours, and we are redoubling our efforts to stabilize our GLP-1 business and make the other changes necessary to return to revenue growth.
Steve Fife: Thanks, Reed, and good afternoon, everyone. Thank you for joining us today. The second quarter presented both challenges and opportunities as we navigated a rapidly evolving competitive landscape while executing on our strategic initiatives. While our Q2 revenue and earnings were down significantly from prior year levels, we were cycling the explosive launch of our MindBody GLP-1 System in October of last year. Despite this headwind, we made significant progress on several key fronts and remained well-positioned for long-term growth in the broader health and wellness ecosystem. As a management team, we acknowledge that our performance during the quarter did not meet your expectation or ours, and we are redoubling our efforts to stabilize our GLP-1 business and make the other changes necessary to return to revenue growth.
Speaker #2: Now I will turn the call over to Steve Fife , the Chief President and Executive Officer of LifeVantage Corp .
Speaker #3: Thanks , good afternoon , and everyone . Thank you for joining us today . The second quarter presented both challenges and opportunities as we navigated a rapidly evolving competitive landscape while executing on our strategic initiatives .
Speaker #3: While our Q2 revenue and earnings were down significantly from prior levels , we were cycling the explosive launch of our mind body GLP in one system October of last year .
Speaker #3: Despite headwinds, we made significant progress on several key fronts and remain well positioned for long-term growth in the broader health and wellness ecosystem.
Speaker #3: As a management team , we acknowledge that our performance during the quarter did not meet your expectation or ours , and we were redoubling our efforts to stabilize our GLP one business and make the other changes necessary to return to revenue growth .
Steve Fife: Let me start by addressing the primary driver for our revenue decline: the competitive dynamics we've experienced in the natural GLP-1 market since launching our MindBody GLP-1 System last year. Our product is scientifically validated and proven effective, and we have a loyal customer base. However, the overall market has become significantly more competitive, with pharmaceutical GLP-1 drugs becoming more accessible and affordable, along with new formulations and formats, including pills. When we launched MindBody, pharmaceutical options were in short supply and cost $several hundred per month to consumers. At that time, MindBody was a compelling value proposition, plus had the added benefit of not requiring any injections and being a proven all-natural solution. Today, pharmaceutical options have come down significantly in price and are increasingly covered by insurance, which has led to much broader use by consumers.
Steve Fife: Let me start by addressing the primary driver for our revenue decline: the competitive dynamics we've experienced in the natural GLP-1 market since launching our MindBody GLP-1 System last year. Our product is scientifically validated and proven effective, and we have a loyal customer base. However, the overall market has become significantly more competitive, with pharmaceutical GLP-1 drugs becoming more accessible and affordable, along with new formulations and formats, including pills.
Speaker #3: Let me start by addressing the primary driver for our revenue decline. The competitive dynamics we've experienced in the natural GLP-1 market since launching our Mind Body GLP-1 system last year.
Speaker #3: Our product is scientifically validated and proven effective , and we have a loyal customer base . However , the overall market has become significantly more competitive with pharmaceutical GLP becoming more one drugs , along accessible and affordable with new formulations and formats including pills .
Steve Fife: When we launched MindBody, pharmaceutical options were in short supply and cost $several hundred per month to consumers. At that time, MindBody was a compelling value proposition, plus had the added benefit of not requiring any injections and being a proven all-natural solution. Today, pharmaceutical options have come down significantly in price and are increasingly covered by insurance, which has led to much broader use by consumers.
Speaker #3: Launched Mindbody when pharmaceutical options were in short supply, costing several hundred dollars per month to consumers. At that time, Mindbody was a compelling value proposition.
Speaker #3: Plus had the added benefit of not requiring any injections and being a proven all natural solution . Today options have come , pharmaceutical down significantly in price and are increasingly covered by insurance , which has led to much broader use by consumers .
Steve Fife: In addition, the drug is now available in more convenient formats, including pills. This rapidly shifting competitive dynamic has dramatically impacted the sale of our GLP-1 offering. As a result, to be conservative, we are recognizing a reserve against a portion of our GLP-1 inventory and evaluating all options to respond to the changing competitive landscape. We are also taking a hard look at cost reduction opportunities to ensure we continue to maintain strong levels of profitability. We remain committed to our MindBody GLP-1 System. It is a great product that works, and we continue to believe strongly in the positioning of natural weight management solutions. The science supporting our approach is robust, and we see this as a temporary market adjustment. What excites us most about this quarter is the continued momentum from our LoveBiome acquisition.
Steve Fife: In addition, the drug is now available in more convenient formats, including pills. This rapidly shifting competitive dynamic has dramatically impacted the sale of our GLP-1 offering. As a result, to be conservative, we are recognizing a reserve against a portion of our GLP-1 inventory and evaluating all options to respond to the changing competitive landscape. We are also taking a hard look at cost reduction opportunities to ensure we continue to maintain strong levels of profitability. We remain committed to our MindBody GLP-1 System. It is a great product that works, and we continue to believe strongly in the positioning of natural weight management solutions. The science supporting our approach is robust, and we see this as a temporary market adjustment. What excites us most about this quarter is the continued momentum from our LoveBiome acquisition.
Speaker #3: In addition , the drug is now available in more convenient formats , including pills . This rapidly shifting competitive dynamic has dramatically sale of impacted the our GLP one offering as a result , to be conservative , we are recognizing a reserve portion against a GLP and evaluating one inventory all options to respond to the changing competitive landscape .
Speaker #3: We are also taking a hard look at cost reduction opportunities to ensure we continue to maintain strong levels of . We remain profitability committed to our mind , body GLP one system .
Speaker #3: It is a great product that works and we continue to believe strongly in the positioning of natural weight management solutions . The science supporting our robust and approach is as a temporary market adjustment see this .
Steve Fife: From an operational perspective, we successfully integrated the LoveBiome team and systems and were realizing the operational synergies. The combined expertise of our teams is already evident in our product development pipeline and go-to-market strategies. Two new products from the LoveBiome portfolio launched earlier this week that should drive engagement, consultant growth, and continue to diversify our product portfolio. First is AXIO X, a new addition to our AXIO line that focuses on pre-workout consumers looking for long-lasting energy, enhancing oxygen uptake, and stamina. Second is PhytoPower B, where the B stands for blocker, an innovative approach that helps to slow sugar absorption and support a healthy metabolism. These launches represent the power of our combined innovation capabilities and demonstrate how the LoveBiome acquisition is already paying dividends in terms of product diversification and market growth.
Steve Fife: From an operational perspective, we successfully integrated the LoveBiome team and systems and were realizing the operational synergies. The combined expertise of our teams is already evident in our product development pipeline and go-to-market strategies. Two new products from the LoveBiome portfolio launched earlier this week that should drive engagement, consultant growth, and continue to diversify our product portfolio.
Speaker #3: What excites us most about this quarter is the momentum continued from our love biome acquisition from an operational perspective , we successfully integrated the Love Biome team and and systems , we're realizing the operational synergies , the combined expertise of teams is of our already evident in our product development pipeline and go to market strategies Two new .
Speaker #3: products from the Love Biome portfolio launched earlier this week that should drive engagement , consultant growth and continue the to diversify our product portfolio .
Steve Fife: First is AXIO X, a new addition to our AXIO line that focuses on pre-workout consumers looking for long-lasting energy, enhancing oxygen uptake, and stamina. Second is PhytoPower B, where the B stands for blocker, an innovative approach that helps to slow sugar absorption and support a healthy metabolism. These launches represent the power of our combined innovation capabilities and demonstrate how the LoveBiome acquisition is already paying dividends in terms of product diversification and market growth.
Speaker #3: axial First is X , new a addition to our axial line that focuses on pre-workout consumers looking for long lasting , energy enhancing oxygen uptake and .
Speaker #3: stamina Second is phyto Power B , where the B stands for blocker . An innovative approach that helps to slow sugar absorption and support a healthy metabolism .
Speaker #3: These launches represent the power of our combined innovation capabilities and demonstrate how the love biome acquisition is already paying dividends in terms of product diversification and market growth over the next couple of months , we will be launching additional products Biome Love , further leveraging an expansive expanding the Love biome portfolio .
Steve Fife: Over the next couple of months, we will be launching additional LoveBiome products, further leveraging and expanding the LoveBiome portfolio. Our now patent-pending P84 product continues to be a hero product with strong positioning in the rapidly growing gut microbiome market. The in vitro testing results we announced in October at our Momentum Academy event further validate the science behind this comprehensive gut health activator, and we're seeing strong adoption among both our combined consultant and consumer base. The Healthy Edge Stack, which combines our proven Protandim Nrf2 Synergizer with P84, has become a lead enrollment story for our consultants. In January, we released the results of our third-party cell study that shows this combination delivers foundational health support throughout the entire body, and the synergistic benefits are resonating strongly with health-conscious consumers. I'm also pleased to report continued progress on our Shopify partnership.
Steve Fife: Over the next couple of months, we will be launching additional LoveBiome products, further leveraging and expanding the LoveBiome portfolio. Our now patent-pending P84 product continues to be a hero product with strong positioning in the rapidly growing gut microbiome market. The in vitro testing results we announced in October at our Momentum Academy event further validate the science behind this comprehensive gut health activator, and we're seeing strong adoption among both our combined consultant and consumer base.
Speaker #3: Now, our patent-pending P84 product continues to be a hero product with strong positioning in the rapidly growing gut microbiome market. The in vitro testing we announced in October at our Results Momentum Academy event further validates the science behind this comprehensive gut health activator, and we're seeing strong adoption among both our combined consultant and consumer base.
Steve Fife: The Healthy Edge Stack, which combines our proven Protandim Nrf2 Synergizer with P84, has become a lead enrollment story for our consultants. In January, we released the results of our third-party cell study that shows this combination delivers foundational health support throughout the entire body, and the synergistic benefits are resonating strongly with health-conscious consumers. I'm also pleased to report continued progress on our Shopify partnership.
Speaker #3: The healthy edge stack , which combines our proven protandim Nrf2 Synergizer with P84 , has become a lead enrollment story for our consultants .
Speaker #3: In January, we released the results of our third-party sell study. It shows that this combination delivers foundational health support throughout the entire body, and the synergistic benefits are resonating strongly with health-conscious consumers.
Steve Fife: This strategic initiative represents a significant modernization in our technology infrastructure and will deliver enhanced e-commerce capabilities that benefit both LifeVantage and our consultants. We're on track for our pilot program and expect this platform to drive improved conversion rates and customer experience. Looking at our international expansion efforts, we continue to see opportunities for growth in key markets. The infrastructure we've built through the LoveBiome integration positions us well to scale our operations globally and serve the evolving needs of health-conscious consumers worldwide. Now, as we look ahead, I'm optimistic about our positioning. We have a comprehensive wellness ecosystem that addresses multiple aspects of human health, from cellular health with Protandim to metabolic wellness with MindBody to gut health with P84 to beauty and longevity with TrueScience Liquid Collagen.
Steve Fife: This strategic initiative represents a significant modernization in our technology infrastructure and will deliver enhanced e-commerce capabilities that benefit both LifeVantage and our consultants. We're on track for our pilot program and expect this platform to drive improved conversion rates and customer experience. Looking at our international expansion efforts, we continue to see opportunities for growth in key markets.
Speaker #3: pleased to also report I'm continued progress on our Shopify partnership . This strategic initiative represents a significant modernization in our technology , infrastructure and will deliver enhanced e-commerce capabilities that benefit both LifeVantage Corp and our consultants .
Speaker #3: We're on track for our pilot, and the program is expected to drive improved conversion rates and customer experience. Looking at our international expansion efforts, we continue to see opportunities for growth in key markets.
Steve Fife: The infrastructure we've built through the LoveBiome integration positions us well to scale our operations globally and serve the evolving needs of health-conscious consumers worldwide. Now, as we look ahead, I'm optimistic about our positioning. We have a comprehensive wellness ecosystem that addresses multiple aspects of human health, from cellular health with Protandim to metabolic wellness with MindBody to gut health with P84 to beauty and longevity with TrueScience Liquid Collagen.
Speaker #3: The infrastructure we built through the biome integration position us well to scale our operations globally and serve the evolving needs of conscious health consumers worldwide .
Speaker #3: Now , as we look ahead , I'm optimistic about our positioning . a We have comprehensive wellness ecosystem that addresses multiple aspects human health , from of health , cellular health with Protandim to metabolic wellness with mind body to get health with P84 to beauty and longevity , with true science , liquid collagen combined with our leading industry evolve Compensation plan and vibrant consulting community , we're uniquely positioned to serve the evolving needs of both consumers and entrepreneurs .
Steve Fife: Combined with our industry-leading evolved compensation plan and vibrant consultant community, we're uniquely positioned to serve the evolving needs of both consumers and entrepreneurs. The direct sales industry continues to evolve, and companies that can combine innovative products, compelling compensation, modern technology, and authentic communities will be the winners. We believe LifeVantage, enhanced by our LoveBiome partnership and strengthened by our commitment to science validation, is perfectly positioned to lead in this new era. We also continue to have a strong balance sheet and proven track record of returning excess capital to shareholders. Since the beginning of fiscal 2024, we've returned over $20 million to shareholders through dividends and share repurchases. Today, we announced a new $60 million share repurchase authorization, underscoring our commitment to the future and commitment to driving long-term value.
Steve Fife: Combined with our industry-leading evolved compensation plan and vibrant consultant community, we're uniquely positioned to serve the evolving needs of both consumers and entrepreneurs. The direct sales industry continues to evolve, and companies that can combine innovative products, compelling compensation, modern technology, and authentic communities will be the winners. We believe LifeVantage, enhanced by our LoveBiome partnership and strengthened by our commitment to science validation, is perfectly positioned to lead in this new era.
Speaker #3: The direct sales industry continues to evolve, and companies that can combine innovative products, compelling compensation, modern technology, and authentic communities will be the winners.
Speaker #3: believe We LifeVantage Corp enhanced by our love bio and partnership and strengthened by our commitment to science validation is perfectly positioned to era new lead in this .
Speaker #3: believe We LifeVantage Corp enhanced by our love bio and partnership and strengthened by our commitment to science validation is perfectly positioned to era new lead in this . We also continue to have a strong balance sheet and proven track record of returning excess capital to shareholders .
Steve Fife: We also continue to have a strong balance sheet and proven track record of returning excess capital to shareholders. Since the beginning of fiscal 2024, we've returned over $20 million to shareholders through dividends and share repurchases. Today, we announced a new $60 million share repurchase authorization, underscoring our commitment to the future and commitment to driving long-term value. The board remains committed to this perspective, as evidenced by the quarterly dividend and new share repurchase program just announced. With that, let me turn the call over to Carl for the detailed review of our financial results and outlook.
Speaker #3: beginning of fiscal 2024 , Since the returned over $20 million to shareholders through dividends and share repurchases . And today , we announced a new $60 million share repurchase authorization , underscoring our commitment to the future .
Steve Fife: The board remains committed to this perspective, as evidenced by the quarterly dividend and new share repurchase program just announced. With that, let me turn the call over to Carl for the detailed review of our financial results and outlook.
Speaker #3: And commitment to driving long-term value. The Board remains committed to this perspective, as evidenced by the quarterly dividend and new share repurchase program.
Speaker #3: Just announced. With that, let me turn the call over to Carl for the detailed review of our financial results and outlook.
Carl Aure: Thank you, Steve, and good afternoon, everyone. Let me walk you through our second quarter financial results. Please note that I will be discussing our Non-GAAP adjusted results where applicable. You can refer to the GAAP to Non-GAAP reconciliations in today's press release for additional details. For the second quarter of fiscal 2026, we delivered net revenue of $48.9 million, which was down 27.8% compared to $67.8 million in the second quarter of fiscal 2025, but was up 2.9% sequentially from the first quarter. The decrease compared to the prior year period was primarily driven by declines in sales of our MindBody GLP-1 System, which decreased $16.2 million compared to the prior year period. This decline was partially offset by sales of the LoveBiome product line, which contributed $4.1 million in revenue following our October acquisition.
Carl Aure: Thank you, Steve, and good afternoon, everyone. Let me walk you through our second quarter financial results. Please note that I will be discussing our Non-GAAP adjusted results where applicable. You can refer to the GAAP to Non-GAAP reconciliations in today's press release for additional details. For the second quarter of fiscal 2026, we delivered net revenue of $48.9 million, which was down 27.8% compared to $67.8 million in the second quarter of fiscal 2025, but was up 2.9% sequentially from the first quarter. The decrease compared to the prior year period was primarily driven by declines in sales of our MindBody GLP-1 System, which decreased $16.2 million compared to the prior year period. This decline was partially offset by sales of the LoveBiome product line, which contributed $4.1 million in revenue following our October acquisition.
Speaker #4: Thank you , Steve , and good afternoon , everyone . Let me walk you through our second quarter financial results . Please note that I will be discussing our non-GAAP adjusted results where applicable .
Speaker #4: You can refer to the GAAP to non-GAAP reconciliation in today's press release for additional details. For the second quarter of fiscal 2026, we delivered net revenue of $48.9 million, which was down 27.8% compared to $67.8 million in the second quarter of fiscal 2025, but was up 2.9% sequentially from the first quarter.
Speaker #4: The decrease compared to the prior period year was primarily driven by declines in sales of our Mind & Body GLP, which, on one system, decreased $16.2 million compared to the prior year period.
Speaker #4: This decline was partially offset by sales of the Love Biome product line , which contributed $4.1 million in revenue . Following our October acquisition , breaking down our regional performance Americas region revenue in the decreased 32.6% to 38.5 million , while revenue in the Asia Pacific and Europe region decreased 2.1% to 10.4 million .
Carl Aure: Breaking down our regional performance, revenue in the Americas region decreased 32.6% to $38.5 million, while revenue in the Asia-Pacific and Europe region decreased 2.1% to $10.4 million. The Americas decline was primarily driven by lower sales of our MindBody GLP-1 System and a 25.2% decrease in total active accounts, mostly from decreases in our active customer base. In Asia-Pacific and Europe, the decline in revenue reflected a 6.5% decrease in total active accounts. Revenues did increase slightly in Japan on a constant currency basis. Our gross profit percentage for Q2 was 74%, down from 80.5% in the prior year period, reflecting a one-time allowance for inventory obsolescence related to MindBody inventory, along with increases in shipping and warehouse-related expenses. Excluding the $2.4 million one-time inventory reserve, our non-GAAP adjusted gross profit percentage was 78.8%.
Carl Aure: Breaking down our regional performance, revenue in the Americas region decreased 32.6% to $38.5 million, while revenue in the Asia-Pacific and Europe region decreased 2.1% to $10.4 million. The Americas decline was primarily driven by lower sales of our MindBody GLP-1 System and a 25.2% decrease in total active accounts, mostly from decreases in our active customer base. In Asia-Pacific and Europe, the decline in revenue reflected a 6.5% decrease in total active accounts. Revenues did increase slightly in Japan on a constant currency basis. Our gross profit percentage for Q2 was 74%, down from 80.5% in the prior year period, reflecting a one-time allowance for inventory obsolescence related to MindBody inventory, along with increases in shipping and warehouse-related expenses. Excluding the $2.4 million one-time inventory reserve, our non-GAAP adjusted gross profit percentage was 78.8%.
Speaker #4: The Americas primarily was by lower sales of our Mind GLP-1 System Body and a 25.2% decrease in active total accounts, mostly from decreases in our active customer base.
Speaker #4: In Asia Pacific and Europe, the decline in revenue reflected a 6.5% decrease in total active accounts. Revenues did increase slightly in Japan on a constant currency basis.
Speaker #4: gross Our profit percentage for the second quarter was 74% , down from 80.5% in the prior year period , reflecting a one time allowance for inventory obsolescence related to mind body inventory , along with increases in shipping and warehouse related expenses .
Speaker #4: Excluding the 2.4 million one time inventory reserve , our non-GAAP adjusted gross profit percentage was 78.8% . and Commissions incentive expense . As a percentage of revenue was 40.7% in the second quarter , compared to 48% in the prior year period .
Carl Aure: Commissions and incentive expense, as a percentage of revenue, was 40.7% in the second quarter compared to 48% in the prior year period. The decrease as a percentage of revenue was primarily due to elevated incentive-related expenses recorded in the prior year period and impact from changes to the mix of customers and consultants in our overall active account base. Selling, general, and administrative expenses were $15.8 million, or 32.3% of revenue, compared to $18.6 million, or 27.5% of revenue in the prior year period. The increase as a percentage of revenue was primarily due to the overall decrease in sales volume and elevated event-related expenses in comparison to the prior year period. GAAP operating income was $0.5 million compared to $3.4 million in the prior year period. Adjusted non-GAAP operating income was $2.6 million compared to $3.9 million in the prior year period.
Carl Aure: Commissions and incentive expense, as a percentage of revenue, was 40.7% in the second quarter compared to 48% in the prior year period. The decrease as a percentage of revenue was primarily due to elevated incentive-related expenses recorded in the prior year period and impact from changes to the mix of customers and consultants in our overall active account base. Selling, general, and administrative expenses were $15.8 million, or 32.3% of revenue, compared to $18.6 million, or 27.5% of revenue in the prior year period. The increase as a percentage of revenue was primarily due to the overall decrease in sales volume and elevated event-related expenses in comparison to the prior year period. GAAP operating income was $0.5 million compared to $3.4 million in the prior year period. Adjusted non-GAAP operating income was $2.6 million compared to $3.9 million in the prior year period.
Speaker #4: The decrease as a percentage of revenue was primarily elevated incentive due to related expenses recorded in the prior year period, impact from changes in mix of customers, and to the consultants.
Speaker #4: In our overall active account base . general and Selling administrative expenses were 15.8 million , or 32.3% of revenue , compared to 18.6 million , 27.5% of revenue , in the prior year period .
Speaker #4: The increase as a percentage of revenue was primarily due to the overall decrease in sales volume and elevated event related expenses . In comparison to the prior year period .
Speaker #4: GAAP operating income or was 0.5 million , compared to 3.4 million in the prior year period . Adjusted non-GAAP operating income was 2.6 million , compared 3.9 million in the prior year period .
Carl Aure: GAAP net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share in the prior year period. Adjusted Non-GAAP net income was $1.9 million, or $0.15 per diluted share, compared to $3 million, or $0.22 per diluted share in the prior year period. Adjusted EBITDA for Q2 was $3.9 million, or 7.9% of revenues, compared to $6.5 million and 9.6% in the same period a year ago. Our financial position remained strong, with $10.2 million of cash and no debt at the end of Q2. We generated $0.5 million of cash from operations during the first six months of fiscal 2026, compared to $8.6 million in the same period in fiscal 2025, mostly due to the timing of incentive payments, payments of other accrued liabilities, and other working capital changes.
Carl Aure: GAAP net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per diluted share in the prior year period. Adjusted Non-GAAP net income was $1.9 million, or $0.15 per diluted share, compared to $3 million, or $0.22 per diluted share in the prior year period. Adjusted EBITDA for Q2 was $3.9 million, or 7.9% of revenues, compared to $6.5 million and 9.6% in the same period a year ago. Our financial position remained strong, with $10.2 million of cash and no debt at the end of Q2. We generated $0.5 million of cash from operations during the first six months of fiscal 2026, compared to $8.6 million in the same period in fiscal 2025, mostly due to the timing of incentive payments, payments of other accrued liabilities, and other working capital changes.
Speaker #4: GAAP net income to was 0.3 million , or $0.02 per diluted share , compared to 2.6 million , or $0.19 per diluted share , in the prior year period .
Speaker #4: Adjusted non-GAAP net income or was 1.9 million , $0.15 per diluted share , compared to 3 million , or $0.22 per diluted share , in the prior year period .
Speaker #4: Adjusted EBITDA for the second quarter was $3.9 million , or 7.9% of revenues , compared to 6.5 million and 9.6% in the same period a year ago .
Speaker #4: Our financial position remains strong , with 10.2 million of cash and no debt . At the end of the second quarter , we generated 0.5 million of cash from operations during the first six months of fiscal 2026 , compared to 8.6 million in the same period .
Speaker #4: In fiscal 2025 , mostly due to the timing of incentive payments . Payments of other accrued liabilities and other working changes . Capital capital expenditures totaled 1.5 million for the months of first six fiscal 2026 , compared to 0.8 million in the prior year period , reflecting our continued investment in technology , infrastructure .
Carl Aure: Capital expenditures totaled $1.5 million for the first six months of fiscal 2026, compared to $0.8 million in the prior year period, reflecting our continued investment in technology infrastructure. We also utilized $3.7 million in cash during the second quarter relating to the closing of the LoveBiome transaction. Turning to capital allocation, we did not repurchase any shares during the second quarter. During the first six months of fiscal 2026, we repurchased 44,000 shares for an aggregate purchase price of $0.6 million. We are also pleased to announce that the company's board of directors recently approved a new $60 million share repurchase program, which replaces in its entirety the prior share repurchase program and authorizes the company to repurchase shares in both open market and private transactions through 31 December 2027. Today, we also announced a quarterly cash dividend of $0.045 per share of common stock.
Carl Aure: Capital expenditures totaled $1.5 million for the first six months of fiscal 2026, compared to $0.8 million in the prior year period, reflecting our continued investment in technology infrastructure. We also utilized $3.7 million in cash during the second quarter relating to the closing of the LoveBiome transaction. Turning to capital allocation, we did not repurchase any shares during the second quarter. During the first six months of fiscal 2026, we repurchased 44,000 shares for an aggregate purchase price of $0.6 million.
Speaker #4: We also utilized $3.7 million in cash during the second quarter relating to the closing of the Love Biome transaction. Turning to capital allocation, we did not repurchase any shares during the second quarter.
Carl Aure: We are also pleased to announce that the company's board of directors recently approved a new $60 million share repurchase program, which replaces in its entirety the prior share repurchase program and authorizes the company to repurchase shares in both open market and private transactions through 31 December 2027. Today, we also announced a quarterly cash dividend of $0.045 per share of common stock.
Speaker #4: During the first six months of fiscal 2026, we repurchased an aggregate 44,000 shares for a purchase price of $0.6 million. We are also pleased to announce that the company's board of directors recently approved a new $60 million share program, which replaces in its entirety the prior share repurchase program and authorizes the company to repurchase shares in both open and private market transactions through December 31st of 2027.
Carl Aure: This dividend will be paid on 16 March 2026, to stockholders of record as of 2 March 2026. Turning to our outlook for fiscal 2026, we now expect revenue in the range of $185 million to 200 million, adjusted EBITDA of $15 million to 19 million, and adjusted earnings per share in the range of $0.60 to $0.80 per fully diluted share. This guidance reflects the current trends in our business, including the competitive dynamics in the GLP-1 market, the positive momentum from our LoveBiome integration, and the expected impact of our February product launches. We remain committed to improving our profitability metrics and driving long-term value for our shareholders. And with that, let me turn the call back over to Steve.
Carl Aure: This dividend will be paid on 16 March 2026, to stockholders of record as of 2 March 2026. Turning to our outlook for fiscal 2026, we now expect revenue in the range of $185 million to 200 million, adjusted EBITDA of $15 million to 19 million, and adjusted earnings per share in the range of $0.60 to $0.80 per fully diluted share. This guidance reflects the current trends in our business, including the competitive dynamics in the GLP-1 market, the positive momentum from our LoveBiome integration, and the expected impact of our February product launches. We remain committed to improving our profitability metrics and driving long-term value for our shareholders. And with that, let me turn the call back over to Steve.
Speaker #4: Today , we also announced a quarterly cash dividend of four and a half cents per share of common stock . This dividend will be paid on March 16th , 2026 , to stockholders of record as of March 2nd , 2026 .
Speaker #4: Turning to our outlook for fiscal 2026 . revenue in expect now We the range of 185 million to 200 million , adjusted of EBITDA 15 million to 19 million , in adjusted earnings per share in the range of $0.60 to $0.80 per diluted share .
Speaker #4: This guidance reflects the current trends in our business, including the competitive dynamics in the GLP-1 market, the positive momentum from our Love Biome integration, and the impact of our February product launches.
Speaker #4: We remain committed to improving our profitability metrics and driving long-term value for our shareholders. And with that, let me turn the call back over to Steve.
Steve Fife: Thanks, Carl. Immediately following our earnings release today, we also issued another press release announcing my planned retirement in April of this year. While these decisions are never easy, I'm confident now is the right time for this transition after accomplishing so much as a team over the last nine years and laying the foundation for LifeVantage's next chapter of growth. The board has been working closely with me on a comprehensive succession planning process for my eventual retirement that ensures leadership continuity and positions LifeVantage for continued success. Leading LifeVantage has been one of the most rewarding experiences of my career, and I am incredibly proud of what we've achieved, from evolving our business model to strengthening our market position, and impacting the lives of thousands of individuals.
Steve Fife: Thanks, Carl. Immediately following our earnings release today, we also issued another press release announcing my planned retirement in April of this year. While these decisions are never easy, I'm confident now is the right time for this transition after accomplishing so much as a team over the last nine years and laying the foundation for LifeVantage's next chapter of growth. The board has been working closely with me on a comprehensive succession planning process for my eventual retirement that ensures leadership continuity and positions LifeVantage for continued success.
Speaker #3: Thanks , Immediately following our earnings Karl . release today , we also issued another press release announcing my planned retirement in April of this year .
Speaker #3: While these decisions are never easy, I'm confident now is the right time for the transition. After accomplishing so much as a team over the nine years and laying the foundation for LifeVantage Corp's next chapter of growth.
Speaker #3: The board has been of closely with me on a comprehensive succession planning process for my eventual retirement . That ensures leadership , continuity and physicians life vantage for continued success .
Steve Fife: Leading LifeVantage has been one of the most rewarding experiences of my career, and I am incredibly proud of what we've achieved, from evolving our business model to strengthening our market position, and impacting the lives of thousands of individuals. Our entrepreneurial opportunity is unlike any other industry, and I have complete confidence in our talented team and the board's ability to guide LifeVantage into its future. Operator, we're now ready to open up the call for questions.
Speaker #3: Leading Life . Vantage has been rewarding experiences of my one of the most career , and I am incredibly proud of what we've achieved .
Speaker #3: From evolving our business model to strengthening our market position and impacting the lives of thousands of individuals, our entrepreneurial opportunity is unlike any other, and I have complete confidence in our talented team and the board's ability to guide LifeVantage into its future. Operator, we're now ready to...
Steve Fife: Our entrepreneurial opportunity is unlike any other industry, and I have complete confidence in our talented team and the board's ability to guide LifeVantage into its future. Operator, we're now ready to open up the call for questions.
Operator: Thank you. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate the line is in the question queue. You may press star two to remove your question from the queue. And for participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question is from Doug Lane with Water Tower Research. Please proceed.
Operator: Thank you. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate the line is in the question queue. You may press star two to remove your question from the queue. And for participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question is from Doug Lane with Water Tower Research. Please proceed.
Speaker #3: We will now open up the call for questions.
Speaker #1: Thank If you you . would like to ask question , a please press Star One on your telephone keypad . A confirmation tone will indicate the line queue .
Speaker #1: question is in the You may press star two to remove your question from the queue . for And participants using speaker equipment and may be to pick up your necessary handset before pressing the star keys .
Doug Lane: Yes. Thank you. And good afternoon, everybody. And Steve, best wishes on your retirement here. All the best. Let me ask about LoveBiome. You mentioned the $3.7 million cash at closing. Is that a transaction cost, or is that the actual purchase price for LoveBiome?
Doug Lane: Yes. Thank you. And good afternoon, everybody. And Steve, best wishes on your retirement here. All the best. Let me ask about LoveBiome. You mentioned the $3.7 million cash at closing. Is that a transaction cost, or is that the actual purchase price for LoveBiome?
Speaker #1: Our first question is from Doug Lane with WaterTower research . Please proceed .
Speaker #5: Yes . Thank you and good afternoon , everybody . And Steve . Best wishes on your retirement here . All the best . Let me ask about love biome .
Speaker #5: You mentioned the $3.7 million cash at closing. Is that a transaction cost, or is that the actual purchase price for Biome Love?
Carl Aure: Yeah, Doug, that's the actual cash transaction price related to the LoveBiome piece. And so I think that we've also talked a little bit more if you look in the details of the 10-Q. And I think we've talked about this in some of our previous discussions. But the deal was structured in two pieces. You had the cash down payment component, which worked out to be that $3.7 million number. And then there's also the ability for a future earnout that's based off of future revenue targets. And so those are really the two components of that. So any further either cash or stock compensation there would be subject to the long-term earnout amounts.
Carl Aure: Yeah, Doug, that's the actual cash transaction price related to the LoveBiome piece. And so I think that we've also talked a little bit more if you look in the details of the 10-Q. And I think we've talked about this in some of our previous discussions. But the deal was structured in two pieces. You had the cash down payment component, which worked out to be that $3.7 million number. And then there's also the ability for a future earnout that's based off of future revenue targets. And so those are really the two components of that. So any further either cash or stock compensation there would be subject to the long-term earnout amounts.
Speaker #4: Yeah , that's the actual cash transaction price related to the love biome piece . And so I think that we've also talked a more .
Speaker #4: little bit you look If in the details of the 10-q , we've talked about I think this in previous some of our discussions .
Speaker #4: the deal was But structured in two pieces . You had the cash down payment component , which worked out to be that $3.7 million number , and then there's also the ability for a future earnout that's based off of future revenue targets .
Speaker #4: And so those are really the two components of that. So any either further cash or stock compensation, there would be subject to the long-term earnout amounts.
Doug Lane: Got it. So that explains about almost half of the $10 million reduction in cash on your balance sheet. What are the one or two other big things that impacted that reduction in cash on your balance sheet from the first quarter?
Doug Lane: Got it. So that explains about almost half of the $10 million reduction in cash on your balance sheet. What are the one or two other big things that impacted that reduction in cash on your balance sheet from the first quarter?
Speaker #5: Got it . So that about explains almost half of the of the 10 million reduction in cash on your balance sheet . What are the big things that that impacted that reduction in cash on your balance sheet from the first quarter ?
Carl Aure: Yeah, that was definitely one of the big items. The other big items, just the timing of accrued payables. If you look at where we were at the end of June, we had some pretty significant accrued payables that just the timing of those turned here during the first half of the year. And then the other component that we had is that one of the other items we do is when we settle stock-based compensation, the withholding tax from employees vesting, the company utilized about $3 million of cash associated with that during the first half of the year. So I would say just between those three buckets, that really accounts for the $10 million decline from where we were in June.
Carl Aure: Yeah, that was definitely one of the big items. The other big items, just the timing of accrued payables. If you look at where we were at the end of June, we had some pretty significant accrued payables that just the timing of those turned here during the first half of the year. And then the other component that we had is that one of the other items we do is when we settle stock-based compensation, the withholding tax from employees vesting, the company utilized about $3 million of cash associated with that during the first half of the year. So I would say just between those three buckets, that really accounts for the $10 million decline from where we were in June. But looking forward, as I look at the back half of the year, I would anticipate that we'll start to really build cash here in the back half of the year from now through the end of our fiscal year.
Speaker #5: Yeah .
Speaker #4: was that was that was definitely one of the one of the big other big items , Yeah . timing of accrued payables . If you look at where items , the That we had some pretty significant accrued payables that just the timing of those turned here during the first half of the year .
Speaker #4: other then the that we And component had is that one of the other items we do is when we settle stock based compensation , the withholding tax from employees , vesting the company utilized about $3 million of cash associated with that during the first half of the year .
Carl Aure: But looking forward, as I look at the back half of the year, I would anticipate that we'll start to really build cash here in the back half of the year from now through the end of our fiscal year.
Speaker #4: So I would say just between those three buckets , that really accounts for the $10 million decline from where we June were in .
Speaker #4: But looking forward , as I look at half of the the back year , I would anticipate that we'll start to really start to build cash here in the back half of the year from now through of our fiscal the end year .
Doug Lane: Okay. That makes sense. And can you give us an update with MindBody so far this year as you enter the weight loss season? What are your marketing plans? How are you approaching that? And what's sort of an early read on how things are going?
Doug Lane: Okay. That makes sense. And can you give us an update with MindBody so far this year as you enter the weight loss season? What are your marketing plans? How are you approaching that? And what's sort of an early read on how things are going?
Speaker #5: Okay , that makes sense . And can you give us an update with Mindbody so far this year as you enter the the weight loss season , what are your what are your marketing plans ?
Carl Aure: Yeah, we kicked off in our fiscal Q2 in November and December a whole kind of go-to-market strategy around MindBody. It included a 20% off sale for the product, which we've carried over through January and now into February. So our product has been discounted by the 20% promotion we have. We also had an event in December that people could qualify for. We call it our Activate 90 event, which is a weekly access to professional trainers, lifestyle, and business individuals that every week on Thursday evenings, they have access to these individuals that talk to them holistically about health and wealth maintenance and management. Those calls, the people qualified to be on those calls live, we record them and now distribute them out, or they're made available to everyone now after the events occur. So that's kind of this weekly reminder for the field.
Steve Fife: Yeah, we kicked off in our fiscal Q2 in November and December a whole kind of go-to-market strategy around MindBody. It included a 20% off sale for the product, which we've carried over through January and now into February. So our product has been discounted by the 20% promotion we have. We also had an event in December that people could qualify for. We call it our Activate 90 event, which is a weekly access to professional trainers, lifestyle, and business individuals that every week on Thursday evenings, they have access to these individuals that talk to them holistically about health and wealth maintenance and management. Those calls, the people qualified to be on those calls live, we record them and now distribute them out, or they're made available to everyone now after the events occur. So that's kind of this weekly reminder for the field.
Speaker #5: How are you approaching that and what sort of an early read on how things are going ?
Speaker #3: Yeah . we we , you know , we kicked in our off and Q2 in , in November to , a kind of go whole market December strategy around mindbody it included a sale for product the , which we've carried over through January .
Speaker #3: And , and now into February . So our product has been discounted by , by the 20% promotion we have . We also had an event in December that people could qualify for .
Speaker #3: We call it our activate 90 event , which was a A is a weekly access to professional trainers , lifestyle and business individual's that on a every week on Thursday evenings .
Speaker #3: They have access to to these individuals that that talk to You know them . holistically health and wealth about maintenance and management . Those calls you know , the people qualified to be on those calls live .
Speaker #3: We we record them . And now distribute them out or they're made available to everyone . Now , you know , after the events are occur .
Carl Aure: We've also, in January, introduced a new feature in our app. Our app has previously been really consultant-driven and to help them with their businesses. But we also now have provided access, a tracking mechanism for customers and consultants to go through and utilize it to help track their calories, their activities, daily reminders, and goal setting. We all know that having those kinds of devices and reminders help all of us kind of be more mindful of our activities, regardless of what it is. And so we were pleased to be able to introduce that in January, and we see and receive positive feedback from that.
Steve Fife: We've also, in January, introduced a new feature in our app. Our app has previously been really consultant-driven and to help them with their businesses. But we also now have provided access, a tracking mechanism for customers and consultants to go through and utilize it to help track their calories, their activities, daily reminders, and goal setting. We all know that having those kinds of devices and reminders help all of us kind of be more mindful of our activities, regardless of what it is. And so we were pleased to be able to introduce that in January, and we see and receive positive feedback from that.
Speaker #3: So that's kind of this , this weekly reminder field . We've for the also in January introduced a new feature in our app , our , our app is previously been really consultant driven .
Speaker #3: And to help businesses . But we now have also provided access and tracking mechanism for customers and consultants to go through and to help , track utilize it their calories , their activities , daily and reminders goal setting .
Speaker #3: all , we all know We you know , having having those kinds of devices and reminders help all of us kind of be more mindful of our activities regardless of what it is .
Speaker #3: we were pleased to be able to introduce in that January . And we see and receive positive feedback from that . We also , I guess , the last thing that I'd say is , is we have a very active campaign where we , we target consumers of of mind body that we're part of .
Speaker #3: we were pleased to be able to introduce in that January . And we see and receive positive feedback from that . We also , I guess , the last thing that I'd say is , is we have a very active campaign where we , we target consumers of of mind body that we're part winback You know , that had utilized it in the and past maybe even going back to a year ago where all of our minds , you know tend to , tend drift a little bit as it relates to weight management in this time of year .
Carl Aure: I guess the last thing that I'd say is we have a very active win-back campaign where we target consumers of MindBody that were part of that had utilized it in the past, and maybe even going back to a year ago where all of our minds tend to drift a little bit as it relates to weight management in this time of year. But win-back campaigns and offering them incentives to come back and get back on the product or try the product again. So it's really, I'd say, multi-pronged in terms of what we're doing to focus our attentions on it.
Steve Fife: I guess the last thing that I'd say is we have a very active win-back campaign where we target consumers of MindBody that were part of that had utilized it in the past, and maybe even going back to a year ago where all of our minds tend to drift a little bit as it relates to weight management in this time of year. But win-back campaigns and offering them incentives to come back and get back on the product or try the product again. So it's really, I'd say, multi-pronged in terms of what we're doing to focus our attentions on it.
Speaker #3: But winback campaigns and offering them incentives to to come back , you and back product know , get or on the try the product it's again .
Speaker #3: So really , I'd say multi-pronged in terms of what we're doing to , to , to focus our attention on that .
Doug Lane: Okay. Getting back to LoveBiome, I see in the queue, I got a chance to look briefly at it, that it contributed about $4 million to the quarter. Does that sound about right? I did not see what if you even disclose how it impacted your consultant numbers and your customer numbers.
Doug Lane: Okay. Getting back to LoveBiome, I see in the queue, I got a chance to look briefly at it, that it contributed about $4 million to the quarter. Does that sound about right? I did not see what if you even disclose how it impacted your consultant numbers and your customer numbers.
Speaker #5: Okay . Getting back to love biome , I see in in the queue , I chance to got a look briefly at it that it contributed about sound about right ?
Speaker #5: I did not see what if even disclosed how it impacted your consultant numbers and your customer numbers .
Carl Aure: Yeah, on the product revenue, that $4 million that we disclosed, that relates to the actual LoveBiome products that were sold during the quarter. So just the products that they brought over through the transaction. There would have also been other revenue of LoveBiome consultants that came over that purchased LifeVantage products. We didn't break that out separately in the Q. So that's what that $4 million refers to, is just the LoveBiome product line itself. And then as far as on the consultants, yeah, we didn't disclose the number of active consultants that came over. But they've been integrated correctly, and that's something that maybe we can speak to at a future time.
Carl Aure: Yeah, on the product revenue, that $4 million that we disclosed, that relates to the actual LoveBiome products that were sold during the quarter. So just the products that they brought over through the transaction. There would have also been other revenue of LoveBiome consultants that came over that purchased LifeVantage products. We didn't break that out separately in the Q. So that's what that $4 million refers to, is just the LoveBiome product line itself. And then as far as on the consultants, yeah, we didn't disclose the number of active consultants that came over. But they've been integrated correctly, and that's something that maybe we can speak to at a future time.
Speaker #4: on the on Yeah , the product revenue , that $4 million that we disclosed that relates to the love biome actual the were sold during the quarter .
Speaker #4: So just the products that they brought over through the transaction, there would have also been other revenue of Love Biome consultants that came over that purchased LifeVantage products.
Speaker #4: break that out We didn't separately in the but queue , that's that what so $4 million refers to is just love biome the product line And then as far consultants we have , we didn't itself .
Speaker #4: disclose the number of active consultants that came over . But , you know , there were they've been integrated correctly and that's something that maybe we can speak to in a future at a future time .
Steve Fife: The other thing, just adding on to that, I did say in my prepared remarks, we launched two LoveBiome products on Monday, actually. We had a kickoff. We had just under 1,000 participants on Monday night and Tuesday night this week where we launched two of LoveBiome's previous products, AXIO X, which fits into our AXIO product line. It's targeting more a higher level of energy, and people use it for pre-workouts or when they would need a boost during the day. And then PhytoPower B, and that B stands for blocker. And so it's a product designed to be not necessarily a daily-use product, but one where almost in anticipation of a big meal, it helps to combat the downside of sugar and carbs as we consume them.
Steve Fife: The other thing, just adding on to that, I did say in my prepared remarks, we launched two LoveBiome products on Monday, actually. We had a kickoff. We had just under 1,000 participants on Monday night and Tuesday night this week where we launched two of LoveBiome's previous products, AXIO X, which fits into our AXIO product line. It's targeting more a higher level of energy, and people use it for pre-workouts or when they would need a boost during the day. And then PhytoPower B, and that B stands for blocker. And so it's a product designed to be not necessarily a daily-use product, but one where almost in anticipation of a big meal, it helps to combat the downside of sugar and carbs as we consume them.
Speaker #3: The other thing , just adding on to that , we I did say in my prepared remarks , you we know , we launched two love biome products on Monday .
Speaker #3: Actually , we had a we had a kickoff . We had just a thousand participants on Monday night and Tuesday this week night where we where we launched two of of love biomes .
Speaker #3: Previous products Axio X , which is a . Fits into our Axio product line . It's targeting more , you know , a higher level of people energy and use it for for need a or when they boost pre-workouts during day the .
Speaker #3: then And phyto Power B and that stands B blocker . for And a so it's product designed to be not necessarily a daily use product , but one where almost , you know , in anticipation of of meal big .
Speaker #3: It a helps to combat , you know , the , the , the of of downside and sugar carbs as we consume them .
Steve Fife: So these kickoff calls that we had on Monday and Tuesday night, it was really expanding the knowledge of those launching the products and then educating the LifeVantage consultants as to the phenomenal products that they are. A lot of it was actually led by LoveBiome individuals because they had access to the products previously. So we're thrilled to now make them available to everyone and expect them to provide some growth in the second half of the year. And then also, I mentioned there will be two additional products that will be launched here that, again, were previous LoveBiome products that will be launched in the next couple of months. And that will kind of then round out the portfolio of products that came to us through that acquisition.
Steve Fife: So these kickoff calls that we had on Monday and Tuesday night, it was really expanding the knowledge of those launching the products and then educating the LifeVantage consultants as to the phenomenal products that they are. A lot of it was actually led by LoveBiome individuals because they had access to the products previously. So we're thrilled to now make them available to everyone and expect them to provide some growth in the second half of the year. And then also, I mentioned there will be two additional products that will be launched here that, again, were previous LoveBiome products that will be launched in the next couple of months. And that will kind of then round out the portfolio of products that came to us through that acquisition.
Speaker #3: So these, these calls that we had on Monday and Tuesday night, the kickoff was really it expanding the knowledge of those launching the, then, products.
Speaker #3: And educating , you know , the , the life as to the consultants products that they are of it , a lot Love by was actually led Biome individuals , you they they had access to the products previously .
Speaker #3: So we're thrilled to now make available to because expect them provide to some growth in the second half of the year . And then also , I mentioned there will be two , two additional products that will be launched here that we're again , we're previous love biome that will be launched products in the next couple of months .
Speaker #3: And that will kind of then round out the portfolio of products that came to us through through that acquisition .
Doug Lane: Okay. Got it. And just looking at the sales, I get the tough comparison with MindBody that we saw coming. But I noticed in the previous three years, in the second quarter, you were north of $50 million, pretty consistent. And then now you're a little bit below that and maybe even more so if you exclude LoveBiome. So I'm just wondering if there's something else, one or two things besides MindBody that maybe wasn't working up to your expectations in the December quarter.
Doug Lane: Okay. Got it. And just looking at the sales, I get the tough comparison with MindBody that we saw coming. But I noticed in the previous three years, in the second quarter, you were north of $50 million, pretty consistent. And then now you're a little bit below that and maybe even more so if you exclude LoveBiome. So I'm just wondering if there's something else, one or two things besides MindBody that maybe wasn't working up to your expectations in the December quarter.
Speaker #5: Okay . Got it . And just looking at at the sales , you know , I get the tough comparison with Mindbody that that , you know , we saw coming .
Speaker #5: I noticed in the previous years, in the second quarter, you were north, pretty, pretty consistent, of $50 million. And you're a bit below that, maybe a little, and maybe so if you exclude Love Biomes.
Speaker #5: even more wondering if I'm there's just something 1 or 2 things besides mindbody else , that maybe wasn't working up to your December quarter ?
Carl Aure: Well, no, I think it has been. We've had a decline in our, especially in our customer base, and modestly in our consultant base. And really, I think the top-line story there is over the last year, MindBody became the enrollment story for many of our consultants. And as some of the challenges that we described in, again, the prepared remarks started to play out throughout the year, the consultants continued to push MindBody, but we lost some momentum around the other hero products that we have, specifically Nrf2 and Collagen. And it's one of the reasons why we're so excited about now having added LoveBiome to the mix and having another hero product that has really reengaged a lot of our consultants with a new story and really opening up a whole new white space for LifeVantage consultants to take a gut health activator too.
Carl Aure: Well, no, I think it has been. We've had a decline in our, especially in our customer base, and modestly in our consultant base. And really, I think the top-line story there is over the last year, MindBody became the enrollment story for many of our consultants. And as some of the challenges that we described in, again, the prepared remarks started to play out throughout the year, the consultants continued to push MindBody, but we lost some momentum around the other hero products that we have, specifically Nrf2 and Collagen. And it's one of the reasons why we're so excited about now having added LoveBiome to the mix and having another hero product that has really reengaged a lot of our consultants with a new story and really opening up a whole new white space for LifeVantage consultants to take a gut health activator too.
Speaker #3: Well , no , I I think it has you know , been , you
Speaker #3: we've had we've a had a decline in our our especially in customer base and modestly in our consultant base and , and really , you the top line story expectations in the know , I think over the last year , mind body the became enrollment for many of story our consultants .
Speaker #3: And as you know , some of the challenges that we described in prepared remarks started to , again , in the out play throughout the year .
Speaker #3: You know , the consultants continued to to mindbody , but push we've we some lost momentum around , you know , the other hero we have , you know and products that and , collagen it's one of the reasons Nrf2 why , you know , we're so excited and about now , having added love biome to the mix and having another hero product that has really reengaged a lot of our consultants with with a new story and really opening whole new white and space for consultants life to take a health gut activator to .
Carl Aure: So it's just that shift doesn't turn overnight. The enthusiasm, excitement about P84, and we've talked, you and I have spoken and we've spoken, in the past around our Healthy Edge Stack, which is a combination of P84 and Nrf2. And that combination, I think, will very shortly be our biggest and highest enrollment product because of how the synergistic benefits and where our consultant base heads are right now. So we're repositioning. MindBody is still a great product for us. It contributed just under 10% of our revenue for the quarter. And the science behind it, the benefits that people feel and are achieving are real. They're demonstrable. But we're trying to now also balance the other great products that we have and incorporating them into that enrollment story.
Carl Aure: So it's just that shift doesn't turn overnight. The enthusiasm, excitement about P84, and we've talked, you and I have spoken and we've spoken, in the past around our Healthy Edge Stack, which is a combination of P84 and Nrf2. And that combination, I think, will very shortly be our biggest and highest enrollment product because of how the synergistic benefits and where our consultant base heads are right now. So we're repositioning. MindBody is still a great product for us. It contributed just under 10% of our revenue for the quarter. And the science behind it, the benefits that people feel and are achieving are real. They're demonstrable. But we're trying to now also balance the other great products that we have and incorporating them into that enrollment story.
Speaker #3: it's so And just , you know , that that shift that doesn't turn . The enthusiasm , excitement about p84 and and , you know , we talked you and I have We spoke in the spoken .
Speaker #3: past our around our healthy edge stack , combination of which is a and p84 and that combination . think will I very shortly be our our biggest and highest enrollment product because of how , you know , the synergistic benefits and , and where our consultants , you know , base heads are right now .
Speaker #3: So we're we're we're repositioning , you know , mind body is is still a great product for us . It eight just under our 10% of revenue for the quarter .
Speaker #3: you And know the behind it , science benefits that the people feel know and are achieving our our their real that we're trying to now also balance .
Speaker #3: Now the other good great products that we have and incorporating them that . You know into story .
Doug Lane: Thanks, Steve. That's a good call. And just one more from me. The Shopify thing you've been talking about, and it looks like it's about to be underway here. Can you take a little bit deeper dive into how you're going to use Shopify? Are there other direct sellers that use Shopify, or are you basically pioneering that for the channel? Just a little bit more color on how Shopify is going to impact your business.
Doug Lane: Thanks, Steve. That's a good call. And just one more from me. The Shopify thing you've been talking about, and it looks like it's about to be underway here. Can you take a little bit deeper dive into how you're going to use Shopify? Are there other direct sellers that use Shopify, or are you basically pioneering that for the channel? Just a little bit more color on how Shopify is going to impact your business.
Speaker #5: That's good Thanks , Steve . And just one more from color . me . You know , the thing you've been about . talking And it Shopify it's looks like about to be here .
Speaker #5: Can you underway little bit deeper into how take a dive Shopify . Are there other direct you're going sellers that use Shopify , or are you basically pioneering that for the channel ?
Carl Aure: Yeah, Shopify is probably the best-known and leader from an e-commerce customer experience platform standpoint. They started off as really a solution to the mom-and-pop small business areas, people that didn't have resources to address the technology associated with owning a business. Since those early years, that's really how they cut their teeth. They built their reputation and the high technology standard that they are known for today. Over the past several years, they have expanded and are working up the food chain, if you will, to larger and larger companies and expanding their capabilities to address bigger companies, e-commerce, and those platforms. There's a lot of benefit that we are going to see from this.
Steve Fife: Yeah, Shopify is probably the best-known and leader from an e-commerce customer experience platform standpoint. They started off as really a solution to the mom-and-pop small business areas, people that didn't have resources to address the technology associated with owning a business. Since those early years, that's really how they cut their teeth. They built their reputation and the high technology standard that they are known for today. Over the past several years, they have expanded and are working up the food chain, if you will, to larger and larger companies and expanding their capabilities to address bigger companies, e-commerce, and those platforms. There's a lot of benefit that we are going to see from this.
Speaker #5: Just a little more on how Shopify is going to impact color ?
Speaker #3: Yeah . You know , Shopify is is , you know , probably the best known and leader from an e-commerce customer experience standpoint .
Speaker #3: They they platform off as as really a solution to the mom and pop small , small business areas . You know , people that didn't have .
Speaker #3: Resources address , to you know , the technology associated with owning a business the and that's years , and really how early those since they cut their teeth .
Speaker #3: They built their reputation the . And technology standard they that known for high And over today . are several years , they have , you know , expanded and are working the up food chain .
Speaker #3: If you will , to larger and larger companies and expanding their capabilities to address bigger and e-commerce and platforms . And , you know , there's there's lot of benefits a that we are see those this .
Carl Aure: Some of them look again. I think I mentioned these in the prepared remarks around conversion rates and just the ease of a customer experience of going through checkout and having a modern approach. I'm sure you've been on our site and purchased products. It has not been a seamless experience for consumers. And the data that's been provided by Shopify in conversions of previous systems to Shopify is pretty staggering around the improvement in that conversion. So that's one aspect of it. The other aspect is just ease of use from a corporate standpoint in when we do promotions, how we display our products, our internal pricing, and how do we get it onto our e-commerce website. The technology that we're currently using is fairly dated, and it takes a lot of internal resources to navigate that.
Steve Fife: Some of them look again. I think I mentioned these in the prepared remarks around conversion rates and just the ease of a customer experience of going through checkout and having a modern approach. I'm sure you've been on our site and purchased products. It has not been a seamless experience for consumers. And the data that's been provided by Shopify in conversions of previous systems to Shopify is pretty staggering around the improvement in that conversion. So that's one aspect of it. The other aspect is just ease of use from a corporate standpoint in when we do promotions, how we display our products, our internal pricing, and how do we get it onto our e-commerce website. The technology that we're currently using is fairly dated, and it takes a lot of internal resources to navigate that.
Speaker #3: You know , the from some of them , you going to again , I think I know , the remarks around prepared and and just companies ease of a customer experience of going through checkout these in and having a modern approach .
Speaker #3: know You sure you've been on , I'm purchased site and It has not seamless experience for been consumers and and the you know , data , that's been provided by Shopify in conversions a systems to Shopify previous pretty staggering around , the , the the the the the improvement in that So conversion .
Speaker #3: that's one aspect of it . other is aspect just ease of use from a corporate standpoint in when we promotions , how we display do products , our our our The internal pricing , and how do we get it , you know , onto our e-commerce website , the , the technology that we're currently is is fairly it takes of a lot internal resources to , to using navigate And so that .
Carl Aure: And so we think that there will be benefits from a process improvement standpoint. And I guess the last one, just again at a high level, is this gives us the opportunity to, although not directly tied to Shopify per se, but gives us the opportunity, and we're taking it, to look at our whole consultant toolbase. So what we refer to as the back office, what their consultants are looking at to run their business, we are taking the opportunity to also make enhancements to that so that it, again, ties in now with the ease of use from a Shopify standpoint. And one of the things about Shopify is, again, they are the industry leader in this space. And by creating this partnership with them, we're really putting our future in a position where we're not chasing what's next.
Steve Fife: And so we think that there will be benefits from a process improvement standpoint. And I guess the last one, just again at a high level, is this gives us the opportunity to, although not directly tied to Shopify per se, but gives us the opportunity, and we're taking it, to look at our whole consultant toolbase. So what we refer to as the back office, what their consultants are looking at to run their business, we are taking the opportunity to also make enhancements to that so that it, again, ties in now with the ease of use from a Shopify standpoint. And one of the things about Shopify is, again, they are the industry leader in this space. And by creating this partnership with them, we're really putting our future in a position where we're not chasing what's next.
Speaker #3: we think that there be will some , you know , benefits a from dated and process improvement standpoint . And , and I guess the last one just a high level , is gives us again , at this the opportunity to , although not directly to , tied to Shopify per se us the opportunity .
Speaker #3: And we're to taking it look our whole . at That gives consultant tool base . you know , what the we refer to as the back office , what , you know , what they're consultants looking are at run to business .
Speaker #3: We taking the are opportunity to enhancements to that . also make So are we that we it ties again , in now with the use from a Shopify ease of And , you know , .
Speaker #3: from a Standpoint . one of the things about Shopify is they again , the industry leader in this space . And by are creating this partnership with them , we're we're really putting our , our in a position where we're chasing what's next .
Carl Aure: We've partnered with someone who is always going to be at the forefront of technology as it relates to e-commerce. So there's going to be a short-term benefit, but knowing that 10 years from now, we're going to continue to be part of a technology trend that is only going to accelerate and be bigger and be part of being able to leverage that and not be in a constant catch-up mode like we are today.
Steve Fife: We've partnered with someone who is always going to be at the forefront of technology as it relates to e-commerce. So there's going to be a short-term benefit, but knowing that 10 years from now, we're going to continue to be part of a technology trend that is only going to accelerate and be bigger and be part of being able to leverage that and not be in a constant catch-up mode like we are today.
Speaker #3: We've who is partnered with always be at the forefront of technology as it relates to someone e-commerce . And so , a there's you know , going to be a short term there's benefit , but you know , ten years knowing now , we're going to continue to be part of a technology trend that is going to bigger and only be be part of being able to that and not , you know , being a constant accelerate up mode catch are today that , .
Doug Lane: Okay. Thank you.
Doug Lane: Okay. Thank you.
Carl Aure: Thanks, Doug.
Carl Aure: Thanks, Doug.
Operator: Our next question is from Ryan Meyers with Lake Street Capital. Please proceed with your question.
Operator: Our next question is from Ryan Meyers with Lake Street Capital. Please proceed with your question.
Speaker #5: Okay . you Thank
Speaker #5: .
Ryan Meyers: Yeah, guys. Thanks for taking my questions. Given the demand and competitive dynamics in the MindBody and GLP-1 space, why do you feel like that's a category that you guys can return to growth in, and why is that a category that you feel like you guys can actually win in?
Ryan Meyers: Yeah, guys. Thanks for taking my questions. Given the demand and competitive dynamics in the MindBody and GLP-1 space, why do you feel like that's a category that you guys can return to growth in, and why is that a category that you feel like you guys can actually win in?
Speaker #4: .
Speaker #4: Doug, thanks. Next, our
Speaker #1: question from is Myers Capital . Lake leverage with your proceed with .
Speaker #6: demand . and You dynamics in mind , the body and glp1 you feel you like that's a guys category that can return in ?
Speaker #6: demand . and You dynamics in mind , the body and glp1 you feel you like that's a guys category that can return space , And growth is that a
Steve Fife: We believe that because of our solution. When you look at our clinical studies, our science, and our results, and you layer on top of that a natural solution versus it doesn't matter really if it's an injectable or a pill that you're taking. It is still introducing the GLP-1 hormone into your body and not helping your body to actually produce and be more effective in the production of that natural hormone. So there are millions of people out there that look more to prevention and natural holistic alternatives that are still going to be very rare and will continue to be interested in our option. And that will always be the case with our products versus synthetic drugs that might tout the same kind of results, but without we are able to do it in a natural way.
Steve Fife: We believe that because of our solution. When you look at our clinical studies, our science, and our results, and you layer on top of that a natural solution versus it doesn't matter really if it's an injectable or a pill that you're taking. It is still introducing the GLP-1 hormone into your body and not helping your body to actually produce and be more effective in the production of that natural hormone. So there are millions of people out there that look more to prevention and natural holistic alternatives that are still going to be very rare and will continue to be interested in our option. And that will always be the case with our products versus synthetic drugs that might tout the same kind of results, but without we are able to do it in a natural way.
Speaker #6: in ? Please
Speaker #3: I
Speaker #3: we that because of our believe are we when you when you solution , you at our clinical studies , our science and our results and you on top of layer that , a natural solution why do versus it doesn't matter if it's an really injectable or a or a pill that you're taking still the introducing one hormone GOP into your , it is Ryan body .
Speaker #3: And not your helping to more effective in the production of that natural and be hormone . So there are there are are produce millions of people that there more to prevention and natural look out alternatives that still be going to very are and will continue to be interested in our are option .
Speaker #3: And that that will always be the case with our products versus synthetic that that might drugs the same results , but kind of without , without , you know , but by but we are able to do it a a , in natural way in .
Ryan Meyers: Got it. And then walk us through the decision to take the inventory charge and just the background information on that.
Ryan Meyers: Got it. And then walk us through the decision to take the inventory charge and just the background information on that.
Speaker #6: Got it . And then walk us through the decision to take the inventory and just the background charge information that
Steve Fife: Yeah, no, I can share some more insight there, Ryan. As you know, when we launched the GLP-1 product last October, a year and a half ago, we just had an incredible response to the demand of that product. We sold out really quickly. We sold out the initial stock that we had within a 3-week period. Just based off of that demand, we really ramped up our supply chain. Based off of that, those early months of demand, we really felt like we needed to build up inventory. Frankly, we got a little bit ahead of ourselves. I think now that we've got the more right-sized demand, that MindBody has really settled in, and we have more visibility into what the seasonality looks like, we decided to take a conservative approach and put a reserve against some of the inventory that we have.
Carl Aure: Yeah, no, I can share some more insight there, Ryan. As you know, when we launched the GLP-1 product last October, a year and a half ago, we just had an incredible response to the demand of that product. We sold out really quickly. We sold out the initial stock that we had within a 3-week period. Just based off of that demand, we really ramped up our supply chain. Based off of that, those early months of demand, we really felt like we needed to build up inventory. Frankly, we got a little bit ahead of ourselves. I think now that we've got the more right-sized demand, that MindBody has really settled in, and we have more visibility into what the seasonality looks like, we decided to take a conservative approach and put a reserve against some of the inventory that we have.
Speaker #4: insight some more
Speaker #4: insight some more there . Ryan . You know , launched the . Yeah . No , I product last October , a year and a half ago , we just as you an when we response to the demand of incredible that product .
Speaker #4: frankly , we got a little bit ourselves . I think , as now that we've got the more right sized mind settled more and we have visibility demand , that seasonality looks .
Steve Fife: The shelf life, I mean, the shelf life of the product is two years, but we felt that it was appropriate to put a reserve against it, to be conservative. We'll still look for other ways to find a way to either sell that or find other uses for it. But that was really the background behind why we went ahead with the inventory reserve.
Carl Aure: The shelf life, I mean, the shelf life of the product is two years, but we felt that it was appropriate to put a reserve against it, to be conservative. We'll still look for other ways to find a way to either sell that or find other uses for it. But that was really the background behind why we went ahead with the inventory reserve.
Speaker #4: We decided to go ahead and look into what the approach is and take a— and put a reserve against some of the inventory that we have.
Speaker #4: The shelf life, the shelf life of the product, like in conservative, two years. But as we felt that it was appropriate to put a reserve against conservative, find a look for.
Speaker #4: other to to ways way We'll still to sell either or for it . uses But find that was really the the background behind other ahead with the went reserve
Ryan Meyers: Got it. And then just lastly, how should we be thinking about the revenue split in the second half of the year? I mean, have you guys seen a rebound at all here in the third quarter? Just any commentary on what we should be thinking about for Q3 and Q4 in terms of revenue split would be helpful.
Ryan Meyers: Got it. And then just lastly, how should we be thinking about the revenue split in the second half of the year? I mean, have you guys seen a rebound at all here in the third quarter? Just any commentary on what we should be thinking about for Q3 and Q4 in terms of revenue split would be helpful.
Speaker #6: just And then lastly , thinking be about revenue the split in second half of the the year ? I mean , have you guys seen a rebound at all here in Just any on what we should be thinking commentary and Q4 of in terms would be helpful the third quarter ?
Steve Fife: Yeah, I think when we think about the back half of the year, we do believe that the MindBody trends have stabilized a bit, and this is a traditional weight loss season. But I do think that we anticipate the build to build from Q3 and then also again into Q4. And especially as we integrate the LoveBiome acquisition and we get their leaders more engaged in the continued rollout of the LoveBiome product, I would anticipate that when you're balancing between the two quarters, that Q4 will likely have a higher proportion of the revenue versus Q3.
Steve Fife: Yeah, I think when we think about the back half of the year, we do believe that the MindBody trends have stabilized a bit, and this is a traditional weight loss season. But I do think that we anticipate the build to build from Q3 and then also again into Q4. And especially as we integrate the LoveBiome acquisition and we get their leaders more engaged in the continued rollout of the LoveBiome product, I would anticipate that when you're balancing between the two quarters, that Q4 will likely have a higher proportion of the revenue versus Q3.
Speaker #6: ?
Speaker #4: I think
Speaker #4: When we think about the back half of the year, we do believe that the Mind, Inventory, and Body trends have stabilized a bit. This is half of the traditional weight loss season.
Speaker #4: But I do think that anticipate we the bill to build also And then into the fourth again and quarter . especially coming from from third quarter .
Speaker #4: integrate the love biome acquisition and we get their more engaged
Ryan Meyers: Got it. That's helpful. Thank you.
Ryan Meyers: Got it. That's helpful. Thank you.
Speaker #4: Q4 will likely have a higher proportion of the revenue leaders .
Steve Fife: Thanks, Ryan.
Steve Fife: Thanks, Ryan.
Ryan Meyers: Thanks, Ryan.
Carl Aure: Thanks, Ryan.
Operator: We have reached the end of our question and answer session. I would like to turn the conference back over to Steve for closing remarks.
Operator: We have reached the end of our question and answer session. I would like to turn the conference back over to Steve for closing remarks.
Speaker #6: That's helpful .
Speaker #6: Thank you .
Speaker #6: Thank you . Thanks ,
Speaker #6: Thank you. Thanks, got it.
Speaker #3: Ryan .
Speaker #4: Ryan Thanks ,
Speaker #4: .
Speaker #1: reached the We have question and answer session . I would like to turn end of our the conference back over closing for remarks to Steve .
Carl Aure: Thanks, operator. Thank you, everyone, for joining us today. Clearly, the second quarter presented some challenges for us. Although that's the case, we do remain confident in our strategic direction and the strength of our diversified both product portfolio and our business model. The successful integration of LoveBiome and our incredible consultants and our recent product and future product launches, our international expansion plans, and our continued focus on scientific innovation position us well for sustainable growth. As we move forward, we remain committed to our mission of activating optimal health processes at a cellular level while providing our independent consultants with the tools and opportunities they need to build successful businesses. I want to extend my appreciation to our dedicated employees, outstanding consultants, loyal stockholders, and faithful customers.
Steve Fife: Thanks, operator. Thank you, everyone, for joining us today. Clearly, the second quarter presented some challenges for us. Although that's the case, we do remain confident in our strategic direction and the strength of our diversified both product portfolio and our business model. The successful integration of LoveBiome and our incredible consultants and our recent product and future product launches, our international expansion plans, and our continued focus on scientific innovation position us well for sustainable growth. As we move forward, we remain committed to our mission of activating optimal health processes at a cellular level while providing our independent consultants with the tools and opportunities they need to build successful businesses. I want to extend my appreciation to our dedicated employees, outstanding consultants, loyal stockholders, and faithful customers.
Speaker #3: Thanks . Operator . And thank you , everyone , for joining us today . The clearly , the second quarter presented for the US .
Speaker #3: although that's And the challenges you know , we do confident in our case , direction and the strength of our diversified , both product and our portfolio model .
Speaker #3: The successful integration of Viome and our incredible consultants and product and our future recent product expansion , and our some continued focus on plans scientific position innovation , well for us growth as we remain committed to our we move activating health optimal processes at a cellular mission of While level .
Speaker #3: providing our Q3 independent with the tools and opportunities need to build successful businesses they . I want to extend my appreciation dedicated employees , outstanding to our consultants , loyal stockholders , and faithful while I'm approaching while customers as CEO , I'm excited about the bright future ahead of LifeVantage Corp .
Carl Aure: And while I'm approaching my end as tenured CEO, I'm excited about the bright future ahead of LifeVantage, and I'm confident in the strong foundation we've built together. We'll continue to drive innovation and growth for years to come. Thank you once again for your continued support and trust in our mission.
Steve Fife: And while I'm approaching my end as tenured CEO, I'm excited about the bright future ahead of LifeVantage, and I'm confident in the strong foundation we've built together. We'll continue to drive innovation and growth for years to come. Thank you once again for your continued support and trust in our mission.
Speaker #3: And I'm confident in the strong foundation together . We'll continue to drive innovation and we've built growth for years to come . Thank you once your support and trust in our continued . mission again for .
Operator: Thank you. This will conclude today's conference. You may disconnect at this time. Thank you for your participation.
Operator: Thank you. This will conclude today's conference. You may disconnect at this time. Thank you for your participation.
